Welcome to our dedicated page for Incannex Healthcare SEC filings (Ticker: ixhl), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Incannex Healthcare's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Incannex Healthcare's regulatory disclosures and financial reporting.
Incannex Healthcare Inc. (IXHL) filed a Form S-8 to register an additional 69,541,101 shares of common stock issuable under its 2023 Equity Incentive Plan, as amended on May 27, 2025, pursuant to the plan’s “evergreen” provision. The filing incorporates prior S-8 registrations for the same plan by reference under General Instruction E.
This expands the share pool available for employee and director equity awards and maintains continuity with the company’s existing plan framework.
Incannex Healthcare Inc. filed a current report to let investors know it has issued a new shareholder update. On October 30, 2025, the company provided an overview for shareholders that highlights its clinical progress, capital discipline, and end‑of‑year 2025 strategic focus.
The details of this update are contained in a press release attached as Exhibit 99.1 to the report, which is incorporated by reference into the filing. The company’s common stock continues to trade on the Nasdaq Stock Market under the symbol IXHL.
Incannex Healthcare Inc. will hold its 2025 annual meeting in a hybrid format at 10:00 a.m. Gulf Standard Time on December 18, 2025, with virtual access and an in‑person option in Dubai.
Stockholders are asked to elect two Class II directors—Dr. George Anastassov and Robert Clark—for three-year terms ending in 2028, and to ratify Grant Thornton Audit Pty Ltd as independent registered public accounting firm for the fiscal year ending June 30, 2026. The board recommends approval of both proposals.
Holders of common stock at the close of business on October 24, 2025 may vote. Shares outstanding were 347,705,507 as of that date. Director elections will be decided by a plurality of votes cast; auditor ratification requires a majority of voting power present and entitled to vote.
Incannex Healthcare (IXHL) disclosed that Nasdaq granted a 180-day extension to regain compliance with the minimum bid price requirement.
The company reported this under Item 8.01 on October 22, 2025. Further details are available in a press release furnished as Exhibit 99.1.
Incannex Healthcare (IXHL) reported a Nasdaq compliance update. The company received a second 180-day grace period, until April 20, 2026, to regain compliance with Nasdaq’s $1.00 minimum bid price rule. The extension follows IXHL’s July transfer from the Nasdaq Global Market to the Nasdaq Capital Market, where it meets all initial listing standards except the bid price requirement.
IXHL can regain compliance if its closing bid price is at least $1.00 for 10 consecutive business days, which Nasdaq may extend to 20 days at its discretion. The company stated it intends to cure the deficiency, including by effecting a reverse stock split if necessary. IXHL’s shares continue to trade on the Nasdaq Capital Market while it remains subject to the market’s other continued listing requirements.
Incannex Healthcare Inc. (IXHL) is an R&D-focused clinical-stage company developing three lead drug candidates: IHL-42X (for obstructive sleep apnea), PSX-001 (psilocybin-based therapy) and IHL-675A (inflammatory and autoimmune indications). Clinical data disclosed for IHL-42X show statistically significant reductions in AHI versus placebo (maximum reductions up to 83% high-dose, 79% low-dose) and clinically meaningful improvements in patient-reported outcomes including fatigue and sleep impairment. Financially the company reported continuing operating losses ($23.8M loss from operations) and net cash outflows from operations (~$12.5M for FY 2025). The company raised gross proceeds of ~$12.5M from an equity offering (9.687M shares at $1.08) and undertook financings, debenture repayments and warrant cancellations during the year. Material risks highlighted include dependence on R&D tax incentives, need for DEA scheduling and FDA/other regulatory approvals, potential listing risk on Nasdaq, and ongoing cash requirements to advance pivotal programs.
Incannex Healthcare Inc. reported positive results from a Phase 2 clinical trial of its investigational therapy PSX-001 (Psi-GAD) for generalized anxiety disorder. The company disclosed the outcome as an other event and directed readers to a detailed press release for more information, indicating that the trial met encouraging benchmarks for this mental health condition. This update highlights progress in Incannex’s clinical development pipeline, although specific efficacy or safety data are contained in the accompanying press release rather than in this report.
Incannex Healthcare Inc. reported that its board has authorized a $20 million share repurchase program. This means the company now has approval to buy back up to that amount of its own common stock, which can reduce the number of shares held by the public over time if the program is used. The update was shared as an other event, with additional details provided in a related press release referenced in the filing.
Incannex Healthcare Inc. (Nasdaq: IXHL) filed a Form 8-K on 8 Aug 2025 announcing that it has received “positive patient-reported outcomes and compelling Phase 2 efficacy data” for IHL-42X, its drug candidate for obstructive sleep apnoea (OSA). The disclosure is provided via a press release attached as Exhibit 99.1 and incorporated under Item 8.01; no financial statements or other quantitative information accompany the notice. The report, signed by CEO Joel Latham, signals meaningful clinical progress for a core pipeline asset but leaves key metrics—statistical significance, safety profile and regulatory timeline—undisclosed. Investors must consult the referenced press release for comprehensive data and next-step development plans.